AstraZeneca PLC published on Friday that its total revenue jumped by 56% annually in the first quarter of 2022 to $11.4 billion. The British vaccine maker posted a 16% increase in core earnings per share to $1.89.

"2022 has started strongly for AstraZeneca. Farxiga achieved $1bn revenue in the quarter, and our Oncology medicines delivered Product Sales growth of 18%, despite COVID-19 continuing to impact cancer diagnosis and treatment," said Pascal Soriot, Chief Executive Officer of AstraZeneca.

Regarding full-year guidance for 2022, AstraZeneca said that total revenues are expected to increase by a high ten-year percentage. In addition, they also mentioned that core EPS is expected to increase by a mid-to-high twenty-year percentage.